Clinical Impact of Pharmacogenetic Risk Variants in a Large Chinese Cohort

Le résumé fourni par la source

ABSTRACT Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcome by choosing the medication and dosage optimized for a patient based on genetic factors that affect drug response 1 . One of the most promising benefits of PGx-guided therapy is the avoidance of adverse reactions 2 . To evaluate the clinical impact of PGx risk variants on adverse outcomes, we performed a retrospective study and analyzed the genetic and clinical data from the largest Han Chinese cohort assembled by the Taiwan Precision Medicine Initiative. We found that nearly all participants carried at least one genetic variant that could affect drug response, with many carrying multiple risk variants. Here we show that detailed analyses of four gene-drug pairs, for which sufficient data exist for statistical power, validate previous findings that PGx risk variants are significantly associated with drug-related adverse events or ineffectiveness. However, the excess risk of side effects or lack of efficacy is small compared to that found in those without the PGx risk variants, and most patients with PGx variants do not suffer from adverse events. Our results point to the need for identifying additional risk factors that cause adverse events in patients without PGx risk variants and factors that protect those with PGx risk variants from adverse events.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.